Dynamix Pharmaceuticals

Dynamix is a venture-backed drug discovery company focused on cancer and autoimmune disease. The company's platform technology, DynamixFit™, is uniquely suited to discovering novel small molecule Type II kinase inhibitors with better clinical prospects. Dynamix has created a proprietary pipeline of new products, which are expected to enter clinical development in 2011.